Pertechnetate Uptake in the Prediction of Early Outcome after Radioiodine Therapy

1989 ◽  
Vol 28 (01) ◽  
pp. 21-25
Author(s):  
T. M. D. Gimlette
Keyword(s):  
Positive Predictive Value ◽  
Radioiodine Therapy ◽  
In Vitro Tests ◽  
First Year ◽  
Thyroid Antibodies ◽  
Early Outcome ◽  
Before And After ◽  
Uptake Test

99mTc-pertechnetate uptake was estimated 8-13 weeks after radioiodine therapy for hyperthyroidism in 132 patients in order to evaluate the usefulness of the uptake test in predicting both persisting hyperthyroidism and the early onset of hypothyroidism during the first year after therapy. The estimation was simple, the result immediately available, and its sensitivities, positive predictive value and its overall accuracy (83%) compared favourably with that of in-vitro tests, FT4I (75%) and FT3I (80%), carried out on the same occasions during the early follow-up period. Pertechnetate uptake can be a useful guide to management by promptly identifying patients likely to need further radioiodine therapy and those with transient or permanent hypothyroidism. The study confirmed some previous findings that hypothyroidism was more frequent in patients with thyroid antibodies and less frequent in patients with nodular thyroids, and it also indicated that hypothyroidism was more frequent in those treated with carbimazole before and after radioiodine, and that hyperthyroidism was more likely to persist in those treated with carbimazole before or after radioiodine.

Factors associated with early and late failure after goniotomy for primary pediatric glaucoma

2018 ◽  
Vol 30 (1) ◽  
pp. 162-167 ◽  
Author(s):  
Dina H Hassanein ◽  
Ahmed Awadein ◽  
Hala Elhilali
Keyword(s):  
Risk Factors ◽  
Intraocular Pressure ◽  
First Year ◽  
Failure Rates ◽  
Factors Associated ◽  
Pediatric Glaucoma ◽  
Late Failure ◽  
Before And After ◽  
The Mean

Purpose: To analyze the risk factors associated with early and late failure after goniotomy for primary pediatric glaucoma. Methods: A retrospective study was done on infants who underwent goniotomy as the initial surgical procedure for primary pediatric glaucoma, and had a follow-up period ⩾48 months after surgery. Early and late failures were defined as intraocular pressure ⩾18 mmHg or signs of glaucoma progression before and after the end of first year, respectively. Results: A total of 81 eyes of 47 children were included. The mean age at the time of surgery was 6.1 ± 6.7 months, 34 children (72.3%) were bilateral. The mean follow-up was 5.9 ± 2.8 years. Of the included eyes, 41 eyes (50.6%) showed success, 25 eyes (30.9%) showed an early failure, and 15 eyes (18.5%) showed a late failure. The mean survival time was 43 months. However, only surgery before the end of the first month and positive consanguinity of the parents (P < 0.01 for both) were independent risk factors for early and late failure of goniotomy for primary pediatric glaucoma. Patients with late failure showed a statistically significant lower preoperative intraocular pressure (P = 0.02). A larger preoperative corneal diameter and a male gender were associated with higher but statistically insignificant failure rates. There were no differences in the early or late failure rates between unilateral and bilateral cases. Conclusion: A positive consanguinity of the parents and surgery before the end of the first month are the major predictors of failure of goniotomy.

scholarly journals In vitro tests for distinguishing possible immune-mediated aplastic anemia from transfusion-induced sensitization

Blood ◽  
1980 ◽  
Vol 55 (2) ◽  
pp. 211-215 ◽  
Author(s):  
BJ Torok-Storb ◽  
C Sieff ◽  
R Storb ◽  
J Adamson ◽  
ED Thomas
Keyword(s):  
T Cells ◽  
T Cell ◽  
Aplastic Anemia ◽  
Colony Growth ◽  
Cell Depletion ◽  
In Vitro Tests ◽  
T Cell Depletion ◽  
Immune Mediated ◽  
Before And After

Abstract Forty-two patients with aplastic anemia (AA) were studied to determine whether or not transfusion-induced sensitization is responsible for the in vitro inhibition by patient lymphocytes of HLA-identical erythroid burst-forming units (BFU-E). The results indicate that lymphocytes from 12 of 34 transfused patients inhibited normal colony growth. In contrast, lymphocytes from none of the 8 untransfused patients demonstrated inhibition. These data were interpreted to mean that coculture studies would not be useful for identifying immune-mediated AA in transfused patients. Therefore, in order to identify possible immune-related AA, we assayed BFU-E from patient blood before and after T-cell depletion. In all 32 patients studied, BFU-E failed to grow from peripheral blood cells before T-cell depletion, but in 8 cases, normal- appearing BFU-E grew after T cells had been removed. Growth of patient BFU-E colonies was inhibited in 6 cases when patient T cells were added back to the culture, indicating that in these 6 patients, an “autoimmune” mechanism may have been present.

Follow-up to the ECVAM Prevalidation Study on In Vitro Tests for Acute Skin Irritation

2002 ◽  
Vol 30 (1) ◽  
pp. 109-129 ◽  
Author(s):  
Valérie Zuang ◽  
Michael Balls ◽  
Philip A. Botham ◽  
Alain Coquette ◽  
Emanuela Corsini ◽  
...  
Keyword(s):  
Skin Irritation ◽  
In Vitro Tests

scholarly journals Therapeutic effectiveness of frozen platelet concentrates for transfusion

Blood ◽  
1981 ◽  
Vol 57 (2) ◽  
pp. 243-249 ◽  
Author(s):  
HM Lazarus ◽  
EA Kaniecki-Green ◽  
SE Warm ◽  
M Aikawa ◽  
RH Herzig
Keyword(s):  
Vapor Phase ◽  
Platelet Concentrate ◽  
In Vitro Tests ◽  
Platelet Concentrates ◽  
Emergency Situations ◽  
Ultrastructural Studies ◽  
Significant Difference ◽  
Before And After ◽  
The Difference

Abstract Six patients received platelet concentrate transfusions from their HLA- identical siblings. Platelet concentrates were administered either fresh, or after being frozen in 10% dimethylsulfoxide, at a slow controlled rate (1 degree C/min) or rapidly (approximately 8 degrees C/min) in the vapor-phase of a liquid nitrogen refrigerator. The median freeze-thaw loss was 13.5%. The mean 1-hr and 20-hr corrected increments in platelet count were calculated for fresh platelet concentrates transfused before and after transfusion with controlled- rate frozen and vapor-phase frozen platelet concentrates. There was no significant difference among the first and second transfusion of fresh platelet concentrates, nor was the difference observed between fresh and controlled-rate frozen platelet concentrates significant. The difference between fresh and vapor-phase frozen platelet concentrates, and between controlled-rate frozen and vapor-phase frozen platelet concentrates were highly significant (p < 0.01). In vitro tests of aggregation using ristocetin and platelet ultrastructural studies paralleled the transfusion experience. Our results indicate that HLA- identical platelet concentrates can be successfully frozen and thawed for transfusion if a slow, controlled rate of freezing is employed. The use of HLA-identical frozen platelet concentrates may be important in emergency situations for the refractory patient and potentially for the establishment of a platelet concentrate bank.

The incidence of occult thyroid disease associated with thyroid antibodies identified on routine autoantibody screening

1982 ◽  
Vol 100 (1) ◽  
pp. 31-35 ◽  
Author(s):  
A. R. Tanner ◽  
Lindsay Scott-Morgan ◽  
R. Mardell ◽  
R. S. Lloyd
Keyword(s):  
Significant Proportion ◽  
Symptomatic Improvement ◽  
Thyroid Function Tests ◽  
Thyroid Antibodies ◽  
Thyroglobulin Antibodies ◽  
Thyroxine Therapy ◽  
Appropriate Treatment ◽  
Microsomal Antibody

Abstract. The presence of thyroid microsomal and/or thyroglobulin antibodies has been recorded over a 2 year period in 15000 consecutive autoimmune profile requests. Where there had been no initial clinical suspicion of thyroid diseases, 332 requests showed positive thyroid antibodies, and of these 63 (19%) had abnormal in vitro thyroid function tests (TFT). No differences were observed between the abnormal and normal groups with respect to the presence of different autoantibodies or to the age and sex distributions. Of these subjects with clinically unsuspected hypothyroidism but with abnormal TFTs, 29% were commenced on thyroxine therapy and experienced a symptomatic improvement, 25% remain well on no therapy and 9% continue on no treatment but with symptoms possibly attributable to hypothyroidism. 3% became clinically hypothyroid during a follow-up period of 2 years. 5% died of unrelated causes and there was inadequate follow-up information on the remainder. This study provides further confirmation that when thyroid antibodies, and in particlar thyroid microsomal antibody, are found unexpectedly, a significant proportion of patients will have biochemical evidence of hypothyroidism and may benefit from appropriate treatment.

scholarly journals MON-624 Follow-Up within the First Year after Radioiodine Therapy for Graves' Disease

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Suemi Marui ◽  
Tomoco Watanabe ◽  
Veronica Mioto ◽  
Nicolau Lima Neto
Keyword(s):  
Radioiodine Therapy ◽  
First Year ◽  
Graves Disease

scholarly journals In vitro tests for distinguishing possible immune-mediated aplastic anemia from transfusion-induced sensitization

Blood ◽  
1980 ◽  
Vol 55 (2) ◽  
pp. 211-215
Author(s):  
BJ Torok-Storb ◽  
C Sieff ◽  
R Storb ◽  
J Adamson ◽  
ED Thomas
Keyword(s):  
T Cells ◽  
T Cell ◽  
Aplastic Anemia ◽  
Colony Growth ◽  
Cell Depletion ◽  
In Vitro Tests ◽  
T Cell Depletion ◽  
Immune Mediated ◽  
Before And After

Forty-two patients with aplastic anemia (AA) were studied to determine whether or not transfusion-induced sensitization is responsible for the in vitro inhibition by patient lymphocytes of HLA-identical erythroid burst-forming units (BFU-E). The results indicate that lymphocytes from 12 of 34 transfused patients inhibited normal colony growth. In contrast, lymphocytes from none of the 8 untransfused patients demonstrated inhibition. These data were interpreted to mean that coculture studies would not be useful for identifying immune-mediated AA in transfused patients. Therefore, in order to identify possible immune-related AA, we assayed BFU-E from patient blood before and after T-cell depletion. In all 32 patients studied, BFU-E failed to grow from peripheral blood cells before T-cell depletion, but in 8 cases, normal- appearing BFU-E grew after T cells had been removed. Growth of patient BFU-E colonies was inhibited in 6 cases when patient T cells were added back to the culture, indicating that in these 6 patients, an “autoimmune” mechanism may have been present.

scholarly journals Vascular Response on a Novel Fibrin-Based Coated Flow Diverter

2021 ◽  
Author(s):  
Ruben Mühl-Benninghaus ◽  
Frederik Fries ◽  
Mara Kießling ◽  
Toshiki Tomori ◽  
Stefanie Krajewski ◽  
...  
Keyword(s):  
Animal Model ◽  
Flow Diverter ◽  
Endothelial Cell Proliferation ◽  
The Novel ◽  
Nano Coating ◽  
Before And After ◽  
Proliferation In Vitro

Abstract Purpose Due to thromboembolic complications and in-stent-stenosis after flow diverter (FD) treatment, the long-term use of dual antiplatelet treatment (DAPT) is mandatory. The tested nano-coating has been shown to reduce material thrombogenicity and promote endothelial cell proliferation in vitro. We compared the biocompatibility of coated (Derivo Heal) and non-coated (Derivo bare) FDs with DAPT in an animal model. Methods Derivo® bare (n = 10) and Derivo® Heal (n = 10) FD were implanted in the common carotid arteries (CCAs) of New Zealand white rabbits. One additional FD, alternately a Derivo bare (n = 5) or Derivo Heal (n = 5), was implanted in the abdominal aorta (AA) for assessment of the patency of branch arteries. Histopathological examinations were performed after 28 days. Angiography was performed before and after FD implantation and at follow-up. Results Statistical analysis of the included specimens showed complete endothelialization of all FDs with no significant differences in neointima thickness between Derivo® bare and Derivo® Heal (CCA: p = 0.91; AA: p = 0.59). A significantly reduced number of macrophages in the vessel wall of the Derivo Heal was observed for the CCA (p = 0.02), and significantly reduced fibrin and platelet deposition on the surface of the Derivo Heal was observed for the AA. All branch arteries of the stented aorta remained patent. Conclusion In this animal model, the novel fibrin-based coated FD showed a similar blood and tissue compatibility as the non-coated FD.

scholarly journals Biodegraded magnetosomes with reduced size and heating power maintain a persistent activity against intracranial U87-Luc mouse GBM tumors

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Edouard Alphandéry ◽  
Ahmed Idbaih ◽  
Clovis Adam ◽  
Jean-Yves Delattre ◽  
Charlotte Schmitt ◽  
...  
Keyword(s):  
Specific Absorption Rate ◽  
Heating Power ◽  
Cellular Internalization ◽  
Persistent Activity ◽  
Before And After ◽  
Anti Tumor Activity ◽  
Nanoparticle Sizes

Abstract Background An important but rarely addressed question in nano-therapy is to know whether bio-degraded nanoparticles with reduced sizes and weakened heating power are able to maintain sufficient anti-tumor activity to fully eradicate a tumor, hence preventing tumor re-growth. To answer it, we studied magnetosomes, which are nanoparticles synthesized by magnetotactic bacteria with sufficiently large sizes (~ 30 nm on average) to enable a follow-up of nanoparticle sizes/heating power variations under two different altering conditions that do not prevent anti-tumor activity, i.e. in vitro cellular internalization and in vivo intra-tumor stay for more than 30 days. Results When magnetosomes are internalized in U87-Luc cells by being incubated with these cells during 24 h in vitro, the dominant magnetosome sizes within the magnetosome size distribution (DMS) and specific absorption rate (SAR) strongly decrease from DMS ~ 40 nm and SAR ~ 1234 W/gFe before internalization to DMS ~ 11 nm and SAR ~ 57 W/gFe after internalization, a behavior that does not prevent internalized magnetosomes to efficiently destroy U87-Luc cell, i.e. the percentage of U87-Luc living cells incubated with magnetosomes decreases by 25% between before and after alternating magnetic field (AMF) application. When 2 µl of a suspension containing 40 µg of magnetosomes are administered to intracranial U87-Luc tumors of 2 mm3 and exposed (or not) to 15 magnetic sessions (MS), each one consisting in 30 min application of an AMF of 27 mT and 198 kHz, DMS and SAR decrease between before and after the 15 MS from ~ 40 nm and ~ 4 W/gFe down to ~ 29 nm and ~ 0 W/gFe. Although the magnetosome heating power is weakened in vivo, i.e. no measurable tumor temperature increase is observed after the sixth MS, anti-tumor activity remains persistent up to the 15th MS, resulting in full tumor disappearance among 50% of treated mice. Conclusion Here, we report sustained magnetosome anti-tumor activity under conditions of significant magnetosome size reduction and complete loss of magnetosome heating power.

Sign in / Sign up

Export Citation Format

Share Document